As Head of Cell Therapy vector and external manufacturing operations, Chris leads a global team working with internal and external partners to deliver vector and regional cell processing manufacturing and analytical operations for all BMS commercial CAR-T assets, plus also collaborating with Cell Therapy Development to support external facing clinical manufacturing and testing activity.
Prior to this, Chris led day-to-day commercial cell therapy manufacturing operations at the Bristol Myers Squibb site in Bothell, Washington manufacturing autologous CAR-T drug product for patients globally. As a member of the Cell Therapy and Development Operations leadership team, he also works with the company’s larger cell therapy network to set the strategic direction for Cell Therapy Operations, to maximize the reach of commercially available cell therapies for patients and support the growth of its cell therapy pipeline.
Chris is a chemist turned engineer with 25+ years of experience working in the Pharma, Biologics & Cell and Gene Therapy sectors. After starting and growing his career in Europe, he has spent the last 13 years in the U.S. in a variety of leadership roles in manufacturing operations. Outside of work, Chris enjoys golf, cooking and travel, ideally with family and friends.